| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
70,650,000 |
| Market
Cap: |
3.62(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$38.62 - $89.12 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
89,721 |
159,721 |
184,721 |
409,721 |
| Total Sell Value |
$6,558,882 |
$10,834,513 |
$12,456,407 |
$25,314,056 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
10 |
12 |
13 |
22 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kulkarni Samarth |
Chief Executive Officer |
• • – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,833 |
194,024 |
|
- |
|
| Tomsicek Michael John |
Chief Financial Officer |
• – – |
2021-03-10 |
4 |
D |
$124.15 |
$167,851 |
D/D |
(1,352) |
1,891 |
|
- |
|
| Tomsicek Michael John |
Chief Financial Officer |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,833 |
3,243 |
|
- |
|
| Ho Tony W |
Executive VP, Head of R&D |
• – – |
2021-03-05 |
4 |
D |
$114.65 |
$181,720 |
D/D |
(1,585) |
35,862 |
|
- |
|
| Ho Tony W |
Executive VP, Head of R&D |
• – – |
2021-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
37,447 |
|
- |
|
| Kulkarni Samarth |
Chief Executive Officer |
• • – |
2021-03-01 |
4 |
D |
$130.25 |
$103,940 |
D/D |
(798) |
182,191 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,213 |
60,749 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2021-03-01 |
4 |
AS |
$0.00 |
$0 |
I/I |
(338,165) |
0 |
|
11% |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
I/I |
60,068 |
4,012 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2021-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
47,536 |
47,536 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2021-02-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,285,027) |
0 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2021-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
248,625 |
6,018 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2021-02-19 |
4 |
S |
$147.79 |
$25,497,840 |
I/I |
(171,003) |
168,831 |
|
-9% |
|
| Kasinger James R. |
General Counsel and Secretary |
• – – |
2021-01-19 |
4 |
AS |
$203.58 |
$5,635,944 |
D/D |
(27,500) |
22,431 |
|
-40% |
|
| Kasinger James R. |
General Counsel and Secretary |
• – – |
2021-01-19 |
4 |
OE |
$51.49 |
$1,415,975 |
D/D |
27,500 |
49,931 |
|
- |
|
| Klein Lawrence Otto |
CBO & COO |
• – – |
2021-01-15 |
4/A |
OE |
$14.43 |
$235,700 |
D/D |
16,334 |
26,942 |
|
- |
|
| Klein Lawrence Otto |
CBO & COO |
• – – |
2021-01-15 |
4 |
AS |
$211.44 |
$5,379,940 |
D/D |
(25,000) |
20,000 |
|
-41% |
|
| Klein Lawrence Otto |
CBO & COO |
• – – |
2021-01-15 |
4 |
OE |
$12.57 |
$344,776 |
D/D |
25,010 |
36,334 |
|
- |
|
| Kulkarni Samarth |
Chief Executive Officer |
• • – |
2021-01-15 |
4 |
AS |
$211.83 |
$4,273,311 |
D/D |
(20,000) |
182,989 |
|
-41% |
|
| Kulkarni Samarth |
Chief Executive Officer |
• • – |
2021-01-15 |
4 |
OE |
$1.81 |
$36,200 |
D/D |
20,000 |
202,989 |
|
- |
|
| Kulkarni Samarth |
Chief Executive Officer |
• • – |
2020-12-29 |
4 |
OE |
$1.81 |
$24,978 |
D/D |
13,800 |
182,989 |
|
- |
|
| Ho Tony W |
Executive VP, Head of R&D |
• – – |
2020-12-21 |
4 |
AS |
$147.05 |
$3,514,610 |
D/D |
(23,551) |
33,964 |
|
-26% |
|
| Ho Tony W |
Executive VP, Head of R&D |
• – – |
2020-12-21 |
4 |
OE |
$16.90 |
$398,012 |
D/D |
23,551 |
57,515 |
|
- |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-12-16 |
4 |
AS |
$147.00 |
$1,095,089 |
I/I |
(7,352) |
339,834 |
|
-8% |
|
| Bolzon Bradley J Phd |
Director |
– • – |
2020-12-16 |
4 |
AS |
$147.00 |
$1,139,177 |
D/D |
(7,648) |
0 |
|
-8% |
|
483 Records found
|
|
Page 6 of 20 |
|
|
2.38 (4.44%) 
